Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma

Glypican-3 is a membrane-bound proteoglycan whose expression has been linked to malignancies through the existence of both mutations and aberrant protein expression. Reports on glypican-3 expression in lung cancer were limited, with some evidence for loss of expression, which suggested a tumor-suppr...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2008-07, Vol.21 (7), p.817-825
Main Authors: Aviel-Ronen, Sarit, Lau, Suzanne K, Pintilie, Melania, Lau, Davina, Liu, Ni, Tsao, Ming Sound, Jothy, Serge
Format: Article
Language:English
Subjects:
Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - metabolism
Carcinoma, Squamous Cell - pathology
DNA Mutational Analysis
Female
Gene Expression
glypican-3
Glypicans - genetics
Glypicans - metabolism
Humans
immunohistochemistry
Laboratory Medicine
Lung - anatomy & histology
Lung - metabolism
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Mutation
Neuroblastoma
Oligonucleotide Array Sequence Analysis
original-article
Pathology
Patients
Proteins
quantitative PCR (qPCR)
RAS mutation
RNA, Messenger - metabolism
RNA, Neoplasm - analysis
Smoking
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glypican-3 is a membrane-bound proteoglycan whose expression has been linked to malignancies through the existence of both mutations and aberrant protein expression. Reports on glypican-3 expression in lung cancer were limited, with some evidence for loss of expression, which suggested a tumor-suppressor role. We sought to evaluate glypican-3 expression in lung cancer at the protein and mRNA levels and correlate it with clinical, histological and genomic characteristics such as RAS mutation status. We used immunohistochemistry on tissue microarray to study glypican-3 expression in 97 patients, evaluated glypican-3 mRNA levels by quantitative polymerase chain reaction in 143 patients and identified RAS mutations by allele-specific oligonucleotide hybridization. We correlated the results with clinical and histological data. Glypican-3 immunostaining was negative in all normal lung tissues, but positive in 23% of lung carcinoma samples. High protein and mRNA expression was associated with squamous histology (positive stain in 55% of squamous cell carcinoma vs 8% of adenocarcinoma, P
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2008.37